{"id":"perforomist-nebulization-copd","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Muscle cramps"},{"rate":null,"effect":"Nervousness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug activates beta-2 adrenergic receptors on bronchial smooth muscle, triggering a cascade that increases intracellular cAMP levels, leading to smooth muscle relaxation and sustained airway dilation. This provides long-acting bronchodilation (approximately 12 hours) that helps reduce airway obstruction and improve breathing in chronic obstructive pulmonary disease.","oneSentence":"Perforomist is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow in COPD patients.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:35:51.669Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic obstructive pulmonary disease (COPD) maintenance therapy"}]},"trialDetails":[{"nctId":"NCT07022418","phase":"PHASE2","title":"Formoterol in Diabetes","status":"RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2025-12-01","conditions":"Diabetic Nephropathies, Diabetic Kidney Disease","enrollment":120},{"nctId":"NCT01488019","phase":"PHASE4","title":"Study to Evaluate the Safety of Long-Term Use of Perforomist® (Formoterol Fumarate)","status":"COMPLETED","sponsor":"Dey","startDate":"2012-03","conditions":"COPD","enrollment":1071},{"nctId":"NCT00909779","phase":"PHASE3","title":"Safety Study of Arformoterol Tartrate Inhalation Solution in Chronic Obstructive Pulmonary Disease (COPD) Subjects","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2009-06","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":841},{"nctId":"NCT01361984","phase":"PHASE4","title":"Sunovion Brovana Versus Serevent Inspiratory Capacity High Resolution Computed Tomography","status":"UNKNOWN","sponsor":"University of California, Los Angeles","startDate":"2011-06","conditions":"Chronic Obstructive Pulmonary Disease, COPD, Emphysema","enrollment":20},{"nctId":"NCT00250679","phase":"PHASE3","title":"Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2005-10","conditions":"Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema","enrollment":443},{"nctId":"NCT00403286","phase":"PHASE2","title":"A Dose-Finding Study Evaluating Safety and Efficacy in Patients With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","sponsor":"Dey","startDate":"2006-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":457}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":276,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Formoterol fumarate"],"phase":"marketed","status":"active","brandName":"Perforomist, nebulization, COPD","genericName":"Perforomist, nebulization, COPD","companyName":"Dey","companyId":"dey","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Perforomist is a long-acting beta-2 adrenergic agonist that binds to beta-2 receptors on airway smooth muscle to cause bronchodilation and improve airflow in COPD patients. Used for Chronic obstructive pulmonary disease (COPD) maintenance therapy.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}